SFSIG
BMY icon

San Francisco Sentry Investment Group’s Bristol-Myers Squibb BMY Stock Holding History

San Francisco Sentry Investment Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$223K Sell
3,340
-714
-18% -$46.6K 0.12% 187
2021
Q1 		$256K Buy
4,054
+1,060
+35% +$66K 0.11% 192
2020
Q4 		$185K Sell
2,994
-2
-0.1% -$123 0.09% 213
2020
Q3 		$181K Sell
2,996
-19
-0.6% -$1.14K 0.09% 198
2020
Q2 		$177K Sell
3,015
-109
-3% -$6.52K 0.09% 189
2020
Q1 		$174K Buy
3,124
+633
+25% +$38.7K 0.11% 164
2019
Q4 		$160K Sell
2,491
-1,825
-42% -$105K 0.07% 228
2019
Q3 		$219K Sell
4,316
-14
-0.3% -$658 0.1% 187
2019
Q2 		$197K Buy
4,330
+1,054
+32% +$49.1K 0.09% 201
2019
Q1 		$157K Sell
3,276
-176
-5% -$8.77K 0.07% 243
2018
Q4 		$179K Sell
3,452
-382
-10% -$20.5K 0.08% 206
2018
Q3 		$238K Buy
3,834
+141
+4% +$8.37K 0.09% 183
2018
Q2 		$204K Sell
3,693
-12,107
-77% -$654K 0.08% 197
2018
Q1 		$1M Buy
15,800
+67
+0.4% +$4.31K 0.29% 71
2017
Q4 		$964K Buy
15,733
+101
+0.6% +$6.32K 0.28% 74
2017
Q3 		$997K Buy
15,632
+750
+5% +$43.8K 0.33% 75
2017
Q2 		$829K Buy
14,882
+2,515
+20% +$137K 0.3% 83
2017
Q1 		$673K Buy
12,367
+300
+2% +$16.5K 0.37% 80
2016
Q4 		$705K Buy
12,067
+649
+6% +$35.5K 0.41% 73
2016
Q3 		$616K Hold
11,418
– – 0.36% 83
2016
Q2 		$840K Hold
11,418
– – 0.52% 63
2016
Q1 		$729K Hold
11,418
– – 0.44% 67
2015
Q4 		$785K Buy
11,418
+116
+1% +$7.67K 0.49% 60
2015
Q3 		$669K Sell
11,302
-800
-7% -$50.8K 0.47% 68
2015
Q2 		$805K Buy
12,102
+118
+1% +$7.78K 0.48% 64
2015
Q1 		$773K Sell
11,984
-490
-4% -$30.7K 0.46% 64
2014
Q4 		$736K Sell
12,474
-210
-2% -$11.8K 0.43% 66
2014
Q3 		$649K Hold
12,684
– – 0.33% 77
2014
Q2 		$615K Hold
12,684
– – 0.29% 84
2014
Q1 		$659K Sell
12,684
-485
-4% -$25.8K 0.21% 105
2013
Q4 		$700K Sell
13,169
-285
-2% -$14.5K 0.24% 99
2013
Q3 		$623K Buy
13,454
+235
+2% +$10.3K 0.24% 101
2013
Q2 		$591K Buy
+13,219
New +$574K 0.21% 99

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

San Francisco Sentry Investment Group's BMY Position: Q2 2021 in Review

San Francisco Sentry Investment Group reduced its Bristol-Myers Squibb (BMY) stake by 18% in Q2 2021, selling an estimated $46.6K and leaving 3,340 shares worth $223K. The position accounts for 0.12% of the portfolio, ranked #187.

San Francisco Sentry Investment Group first reported a position in BMY in Q2 2013 and has held it in 33 quarters since. The position peaked at $1M in Q1 2018. 2,370 funds tracked by Wall St. Rank hold BMY as of Q2 2021.

  • San Francisco Sentry Investment Group held 3,340 shares of Bristol-Myers Squibb worth $223K as of Q2 2021.
  • San Francisco Sentry Investment Group sold 714 Bristol-Myers Squibb shares in Q2 2021, an estimated $46.6K.
  • Bristol-Myers Squibb made up 0.12% of San Francisco Sentry Investment Group's portfolio in Q2 2021, its #187 holding.
  • San Francisco Sentry Investment Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 33 quarters since.
  • San Francisco Sentry Investment Group's Bristol-Myers Squibb position peaked at $1M in Q1 2018.
  • 2,370 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.